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Abstract Link protein and aggrecan of the extracellular matrix 
each contain two proteoglycan tandem repeat (PTR) domains 
that interact with hyaluronate. Consensus secondary structure 
predictions for 59 PTR sequences and 129 C-type lectin 
sequences give similar patterns of two a-helices and up to seven 
~strands. Protein fold recognition analyses show that the 59 
PTR sequences are highly compatible with the C-type lectin 
crystal structure. The predicted fold consists of a conserved motif 
formed from an antiparaHel IS-sheet flanked by two s-helices, the 
motif being attached to two distinct types of ~-sheet region in the 
two superfamilies. Arg9 or Lys l l  on an exposed loop and up to 
three other Arg residues in the ~-sheet region are conserved and 
may form part of a hyaluronate binding site. 
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1. Introduction 
Proteoglycans consist of many long anionic polysaccharide 
chains (glycosaminoglycans) covalently attached to an ex- 
tended central protein core which stabilise the extracellular 
matrix [1,2]. Aggrecan is the archetypal member of this group, 
and contains a globular N-terminal region G1 that is con- 
structed from an immunoglobulin fold domain and two pro- 
teoglycan tandem repeat (PTR) domains [1,2]. A second re- 
gion G2 in aggrecan next to G1 contains two PTRs. Link 
protein also contains one immunoglobulin fold and two 
PTR domains [3]. G1 and link protein form a very stable 
ternary complex with hyaluronate. X-ray and neutron solu- 
tion scattering and electron microscopy show that G1, link 
protein and the ternary complex possess compact structures 
[4-6]. Aggrecan also contains a globular C-terminal region 
(G3) with variable numbers of epidermal growth factor do- 
mains, followed by a carbohydrate recognition domain (CRD) 
belonging to group I of the C-type lectin superfamily [7], and 
a short consensus/complement repeat domain. 
Both the PTR and CRD superfamilies are associated with 
carbohydrate binding, where the PTR binds hyaluronate and 
the CRD binds a variety of oligosaccharide ligands. The PTR 
superfamily includes the CD44 group of cell surface receptors. 
Our previous consensus econdary structure analyses of 15-20 
PTR sequences indicated the occurrence of a-helices (A) and 
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~-strands (B) in the sequence BABABBB [8]. This is very 
similar to our recent consensus econdary structure prediction 
for 129 CRD sequences which gave BABABBBB [9]. Crystal 
structures of rat mannose binding protein and human E-se- 
lectin in the CRD superfamily are available for comparison 
with these predictions [10,11]. 
Here, this similarity between the PTR and CRD superfami- 
lies is examined further, using our approach to predict a pro- 
tein fold prior to its crystal structure determination [12-14]. 
Consensus tructure predictions were performed for 59 PTR 
sequences for comparison with our analysis of 129 CRD se- 
quences. Protein fold recognition analyses were performed in 
which the 59 PTR sequences were scored against 254 known 
folds. These analyses howed a relationship between the PTR 
and CRD folds. Molecular graphics modelling of the PTR 
based on CRD crystal structures [10,11] showed that the 
PTR and CRD structures are characterised by a conserved 
et-helix/13-sheet core and distinct 13-sheet regions. The model 
was examined for information relating to a hyaluronate bind- 
ing site. 
2. Methods 
2.1. Sequence alignment and predictions 
A total of 59 PTR (48 proteoglycan, 2 TSG-6 and 9 CD44) se- 
quences were extracted from the ENTREZ CD-ROM database (Na- 
tional Center for Biotechnology Information) (Fig. 1). The sequence 
alignment followed that for 15-20 PTR sequences [4,8]. 129 CRD 
sequences were extracted from ENTREZ [9]. Five different methods 
were used to yield averaged three-state or four-state secondary struc- 
ture predictions, based on the classical GOR I and GOR III and 
Chou-Fasman statistical methods [15-18], together with the environ- 
ment-dependent amino acid substitution probability method SA- 
PIENS [19] and the neural networking method PHD [20]. The se- 
quence alignment was used to compute the mean hydropathy using 
a consensus hydrophobicity scale [15], and solvent accessibilities were 
computed by the SAPIENS and PHD approaches [21,22]. 
2.2. Protein foM recognition and modelling 
All 59 PTR sequences were subjected to optimal fitting to a library 
of 254 protein folds using THREADER [23]. Threadings were com- 
puted in terms of pairwise interaction energies in order to evaluate the 
fit of each PTR sequence to a particular fold conformation. The 
comparison was represented as Z-scores [=(Energy--Mean)/Standard 
Deviation]. A high structural match requires a Z-score of less than 
-2.7. The Z-scores were sorted for input into SUM_THREADER 
[14] to calculate the average Z-score and position of each of the 254 
folds from the 59 threadings. 
Protein structures were visualised using INSIGHT II 95.0 (Biosym/ 
MSI, San Diego, CA, USA) or SETOR [24] on Silicon Graphics 
INDY Workstations. The rigid body fragment assembly method as 
used in HOMOLOGY was used to model the first PTR of human link 
protein using the crystal structure for rat mannose-binding protein 
(Brookhaven code: 2msb [10]). After the definition of a 65-residue 
protein core, deletions were made in 2msb to define 33 loop residues 
in three segments in the PTR, at residues 41-47, 54-72 and 77-82. The 
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loop conformations were constructed from a database of Brookhaven 
fragments. All the sidechains were mutated to those in the PTR. 
Energy refinements using DISCOVER were performed at the loop 
splice junctions, then on the loops, then on the mutated core residues. 
Distance constraints in these refinements were used to join Cys45 and 
Cys66 in the PTR. The refinements improved the connectivity of the 
model and reduced the proportion of bad contacts or stereochemistry, 
as confirmed by the use of PROCHECK [25]. 
The DSSP program [26] was used to assign the observed secondary 
structure as [8-strands (DSSP codes E and B), c~-helices (I, H, or G), 
and loop regions (s, t and .). Sidechain solvent accessibilities were 
calculated by the Lee and Richards method in COMPARER [27] 
on a scale from 0 to 9 for each residue, where 0 corresponds to 0- 
10% solvent exposure, 1corresponds to 11 20% solvent exposure, and 
so on. 
PTR SEQUENCES 
PLK HUMAN Llnk 
PLK HUMAN' Llnk 
PLK PIG Llnk 
PLK PIG' Link 
406053 (bovine) Link 
406053'(bovine) Link 
$42938 (horse) Link 
$42938' (horse) Link 
PLK RAT Link 
PLK-RAT' Link 
PLK-CHICK Link 
PLK-CHICK' Link 
PGCA_HUMANI Aggrecan 
PGCA_HUMANI'Aggrecan 
PGCA HUMAN2 Aggrecan 
PGCAHUMAN2'Aggrecan 
$29139(I) Aggrecan 
S29139(i') Aggrecan 
PGCA RATI Aggrecan 
PGCA RAT]' Aggrecan 
PGCA-RAT2 Aggrecan 
PGCA RAT2' Aggrecan 
A55182(I) Aggrecan 
A55182(1') Aggrecan 
A55182(2) Aggrecan 
A55182(2') Aggrecan 
$39796(I) Aggrecan 
$39796(I') Aggrecan 
$39796(2) Aggrecan 
S39796(2') Aggrecan 
A54423(I) Brevlcan 
A54423(I') Brevican 
$49126(I) Brevican 
$49126(I') Brevican 
$44097(1) Brevlcan 
S44097(1') Brevican 
886890(I) Brevlcan 
886890(I') Brevican 
$28764(I) Neurocan 
$28764(I') Neurocan 
$52781(I) Neurocan 
$52781(I') Neurocan 
PGCS HUMANI Verslcan 
PGCS HUMAN1'Versfcan 
862461(I) Versican 
862461(I') Verslcan 
A47171(I) Verslcan 
A47171(I') Versican 
A41735 (human) TSG-6 
A47290 (rabblt)TSG-6 
CD4H HUMAN CD44 
CD4X HUMAN CD44 
CD44 PAPHA CD44 
A53286 (bovine) CD44 
CD44 HORSE CD44 
$45305 (dog) CD44 
CD44 CRISP CD44 
CD44 RAT CD44 
CD44-MOUSE CD44 
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FPYFPRLGRYNLNFHEAQQACLDQDAVIASFDQLYDAWRG GLDWCNAGWLSDGSVQYPITKPREPCGGQNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLNDGAQIAKVGQIFAAWKILGYDRCDAGWLADGSVRYPISRPRRRCSPTE AAVRFV 
FPYFPRLGRYNLNFHEAQQACLDQDAVIASFDQLYDAWRG GLDWCNAGWLSDGSVQYPITKPREPCGGQNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLNDGAQIAKVGQIFAAWKLLGYDRCDAGWLADGSVRYPISRPRRRCRPNE AAVRFV 
FPYFPRLGRYNLNFHEAQQACLDQDAVIASFDQLYDAWRS GLDWCNAGWLSDGSVQYPITKPREPCGGQNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLNDGAQIAKVGQIFAAWKLLGYDRCDAGWLADGSVRYPISRPRRRCSPSE AAVRFV 
FPYFPRLGRYNLNFHEAQQACLDQDAVIASFDQLYDAWRG GLDWCNAGWLSDGSVQYPITKPREPCGGQNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLKDGAQIAKVGQIFAAWKLLGYDRCDAGWLADGSVRYPISRPRRRCSPTE AAVRFV 
FPYFPRLGRYNLNFHEARQACLDQDAVIASFDQLYDAWRG GLDWCNAGWLSDGSVQYPITKPREPCGGQNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLNDGAQIAKVGQIFAAWKLLGYORCDAGWLADGSVRYPISRPWRRCSPTE AAVRFV 
FPYSPRLGRYNLNFHEAQQACLDQDSIIASFDQLYEAWRS GLDWCNAGWLSDGSVQYPITKPREPCGGKNTV PGVRNY 
GRFYYLIHPTKLTYDEAVQACLKDGAQIAKVGQIFAAWKLLGYDRCDAGWLADGSVRYPISRPRKRCSPNE AAVRFV 
FHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYED 
GEVFYATSPEKFTFQEAANECRRLGARLATTGHVYLAWQA 
FHYRPGPTRYSLTFEEAQQACPGTGAVIASPEQLQAAYEA 
GEVFFATRLEQFTFQEALEFCESHNAT ATTGQLYAAWSR 
FHYRAISXRYTLDFDRAQRACLQNSAIIATPEQLQAAYED 
GEVFYATSPEKFTFQEAANECRRLGARLATTGQLYLAWRG 
FHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYED 
GEVFYATSPEKFTFQEAANECRTVGARLATTGQLYLAWQG 
FHYRPGSTRYSLTFEEAQQACIRTGAAIASPEQLQAAYEA 
GEVFFATQMEQFTFQEAQAFCAAQNATLASTGQLYAAWSQ 
FHYRAISTRYTLDFDRAQRACLQNSAIIATPEQLQAAYED 
GEVFYATSPEKFTFQEAANECRRLGARLATTGQLYLAWQG 
FHYRPGSTRYSLTFEEAQQACMHTGAIIASPEQLQAAYEA 
GEVFFATRLEQFTFQEARAFCAAQNATLASTGQLYAAWSQ 
FHYRAISTRYTLNFERAKQACIQNSAVIATPEQLQAAYED 
GKVFYATSPEKFTFQEAFDKCHSLGAHLATTGELYLAWKD 
FHYRAATSRYAFSFIQAQQACLENNAVIATPEQLQAAYEA 
GEVFFATQPEQFTFQEAQLYCESQNATLASAGQLHAAWKQ 
FLYREGSARYAFSFAGAQEACARIGARIATPEQLYAAYLG 
GELFLGAPPDKLTLEEARTYCQERGAKIATTGQLYAAWDG 
FLYREGSARYAFSFAGAQEACARIGARIATPEQLYAAYLG 
GELFLGAPPGKLTWEEARDYCLERGAQIASTGQLYAAWNG 
FLYREGSARYAFSFARAQEACARIGARIATPEQLYAAYLG 
GELFLGAPPDNVTLEEATAYCRERGAEIATTGQLYAAWDG 
FLYREGSARYAFSFAGAQEACARIGARIATPEQLYAAYLG 
GELFLGAPPSKLT~EEARDYCLERGAQIASTGQLYAAWNG 
FHYRAARDRYALTFAEAQEACHLSSATIAAPRHLQAAFED 
GEVFYVGPARRLTLAGARALCQRQGAALASVGQLRLAWHE 
FHYRAARDRYALTFAEAQEACRLSSATIAAPRHLQAAFED 
GEVFYVGPARRLTLAGARAQCQRQGAALASVGQLHLAWHE 
FHYRAATSRYTLNFEAAQKACLDVGAVIATPEQLFAAYED 
GDVFHLTVPSKFTFEEAAKECENQDARLATVGELQAAWRN 
FHYRAATSRYTLNFAAAQQACLDIGAVIASPEQLFAAYED 
GDVFHITAPSKFTFEEAEAECTSRDARLATVGELQAAWRN 
FHYRAATSRYTLNFTQAQQTCLDNGAVIASPEQLKAAYED 
DEVVHVSVPEKLTFEEAKELCRKRDGVLASVGNMYVAWRN 
YHREARSGKYKLTYAEAKAVCEFEGGHLATYKQLEAARKI 
YHREARSGKYKLTYAEAKAVCEFEGGRLATYKQLEAARKI 
VFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSI 
VFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSI 
IYHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSI 
VFHVEKNGRYSISKTEAADLCKAFNSTLPTMAQMEAARNI 
VFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMQKALNI 
VFHVEKNGRYSISRTAAADLCKAFNSTLPTMAQMERALSV 
VFHVEKNGRYSISRTEAADLCQAFNSTLPTMDQMVMALSK 
VFHVEKNGRYSISRTEAADLCEAFNTTLPTMAQMELALRK 
VFHVEKNGRYSISRTEAADLCQAFNSTLPTMDQMKLALSK 
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GFWDKDKSRYDVFCFTSNFN 
GFPDKKHKLYGVYCFRA YN 
GFWDKDKSRYDVFCFTSNFN 
GFPDKKHKLYGVYCFRA YN 
GFWDKDKSRYDVFCFTSNFN 
GFPDKKHKLYGVYCFRA YN 
GFWDKEKSRYDVFCFTSNFN 
GFPDKKHKLYGVYCFRA YN 
GFWDKDKSRYDVFCFTSNFN 
GFPDKKHKLYGVYCFRA YN 
GFWDKERSRYDVFCFTSNFN 
GFPDKKRKLYGVYCFRA YN 
GFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVRTY GIRDTNET 
GMDMCSAGWLADRSVRYPISKARPNCGGNL LGVRTVYVHANQTGYPDPSSR 
GYEQCDAGWLRDQTVRYPIVSPRTPCVGDKDSSPGVRTY GVRPSTET 
GLDKCYAGWLADGSLRYPIVTPRPACGGDK PGVRTVYLYPNQTGLPDPLSR 
GFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVITY GIRDTNET 
GMDMCSAGWLADRSVRYPISI(ARPNCGGNL LGVRTVYLHANQTGYPDPSSR 
GFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVRTY GIRDTNET 
GMDMCSAGWLADRSVRYPISKARPNCGGNL LGVRTVYLHANQTGYPDPSSR 
GYEQCDAGWLQDQTVRYPIVSPRTPCVGDKDSSPGVRTY GVRPSSET 
GLDKCYAGWLADGTLRYPIVNPRPACGGDK PGVRTVYLYPNQTGLPDPLSK 
GFHQCDAGWLADQTVRYPIHTPREGCYGDKDEFPGVRTY GIRDTNET 
GMDMCSAGWLADRSVRYPISKARPNCGGNL LGVRTVYLHANQTGYPDPSSR 
GYEQCDAGWLQDQTVRYPIVSPRTPCVGDKDSSPGVRTY RVRPSSET 
GLDKCYAGWLADGTLRYPIITPRPACGGDK PGVRTVYLYPNQTGLPDPLSK 
YDVYCFAEEME 
YDAICYTGEDFVD 
YDVYCFVDRLE 
HHAFCFRGISAVP 
YDVYCFAEEME 
YDAICYTGEDFVD 
YDVYCFAEEME 
YDAICYTGEDFVD 
YDVYCYVDKLE 
HHAFCFRGVSVVP 
YDVYCFAEEME 
YDAICYTGEDFVD 
YDVYCYVDKLE 
HHAFCFRGVSVAP 
GYEQCDAGWLADQTVRYPIHLPRERCYGDKDEFPGVRTY GVRETDET YDVYCYAEQMQ 
GMDMCSAGWLADRSVRYPISRARPNCGGNL VGVRTVYLNPANQTGYPHPSSRYDAICYSGODFEA 
GFDQCDAGWLRDQTVRYPIVNPRSNCVGDKESSPGVRSY RMRPASET YDVYCYIDRLK 
GLDRCYPGWLADGSLRYPIVSPRPACGGDA PGVRTIYQHHNQTGFPDPLSR 
GYEQCDAGWLSDQTVRYPIQTPREACYGDMDGFPGVRNY GVVDPDDL 
GLDRCSSGWLSDGSVRYPIVTPSQRCGGGL PGVKTLFLFPNQTGFPNKHSR 
GYEQCDAGWLSDQTVRYPIQNPREACYGDMDGYPGVRNY GVVGPDDL 
GLDRCSPGWLADGSVRYPIITPSQRCGGGL PGVKTLFLFPNQTGFPSKQNR 
GYEQCDAGWLSDQTVRYPIQTPREACYGDMDGFPGVRNY GLVDPDDL 
GLDRCSPGWLADGSVRYPIVTPSQRCGGGL PGVKTLFLFPNQTGFPNKYSR 
GYEQCDAGWLSDQTVRYPIQNPREACSGDMDGYPGVRNY GVVGPDDL 
GLDRCSPGWLADGSVRYPIITPSQRCGGGL PGVKTLFLFPNQTGFPSKQNR 
GFDNCDAGWLSDRTVRYPITQSRPGCYGDRSSLPGVRSY GRRDPQEL 
GLDQCDPGWLADGSVRYPIQTPRRRCGGSA PGVRTVYRFANRTGFPAPGAR 
GFDNCDAGWLSDRTVRYPITQSRPGCYGDRSSLPGVRSY GRRDPQEL 
GLDQCDPGWLADGSVRYPIQTPRRRCGGPA PGVRTVYRFANRTGFPAPGAR 
GFEQCDAGWLADQTVRYPIRAPRVGCYGDKMGKAGVRTY GFRSPQET 
GFDQCDYGWLSDASVRHPVTVARAQCGGGL LGVRTLYRFENQTGFPPPDSR 
GFEQCDAGWLSDQTVRYPIRAPREGCYGDMMGKEGVRTY GFRSPQET 
GFDQCDYGWLSDASVRHPVTVARAQCGGGL LGVRTLYRFENQTCFPLPDSR 
GFEQCDAGWLSDQTVRYPIRHPRIGCFGDKMGKKGVRTY GRRFPNET 
GFDQCDYGWLADGSVRYPASVARPQCGGGL LGVRTLYRYENQTGFPYPDSK 
GFHVCAAGWMAKGRVGYPIVKPGPNCGFGK TGIIDY 
GFHVCAAGWMAKGRVGYPIVKPGSNCGFGK TGIIDY 
GFETCRYGFIEGHVVIPRIHPNSI CAANN TGVYIL 
GFETCRYGFIEGHVVIPRIHPNSl CAANN TGVYIL 
GFETCRYGFIEGHVVIPRIHPNSI CAANN TGVYIL 
GFETCRYGFIEGHVVIPRIHPNSI CAANN TGVYIL 
GFETCRIGFIEGHVVIPPIHPNSI CAANN TGVYIL 
GFETCRYGFIEGHVVIPRIQPNAI CAANH TGVYIL 
GFETCRYGFIEGHVVIPRIQPNAI CAANH TGVYIL 
GFETCRYGFIEGHVVIPRIHPNAI CAANN TGVYIL 
GFETCRYGFIEGNVVIPRIHPNAI CAANH TGVYIL 
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HHAFCFRALPSVV 
YDVYCYAEELN 
FNVYCFRDSAQPS 
YDVYCYAEDLN 
FNVYCFRDSAHPS 
YDIYCYAEDLN 
FNVYCFRDSGQPS 
YDVYCYAEDLN 
FNVYCFRDSAHPS 
YDVYCFARELG 
FDAYCFRAHHHTP 
YDVYCFARELG 
FDAYCFRAHHHTA 
YDVYCYVDHLD 
FDAYCFKRRMSDL 
YDVYCYVDHLD 
FDAYCFKRRLSOM 
YDVYCYVEHMQ 
FDAYCYERKKIVS 
GIRLNRSERWDAYCYNPHAKE 
GIRLNRSERWDAYCYNPHAKE 
TSNTSQ YDTYCFNASA 
TYNTSQ YDTYCFNASA 
TSNTSQ YDTYCFNASA 
TSNTSQ YDTICFNASAPPG 
TSNTSQ YDTYCFNASA 
ISNTSQ YDTYCFNASA 
TSNTSH YDTYCFNASA 
LASNTSH YDTYCFNASA 
VTSNTSH YDTYCFNASA 
80 90 
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Fig. 1. Alignment for 59 PTR sequences. Sequences are identified by their SWISSPROT or PIR accession ames or numbers. The aggrecan G1 
and G2 sequences are in the order: human, pig, rat, mouse, chicken. Those for brevican are in the order: bovine, rat, cat, mouse. Those for 
neurocan are in the order: rat, mouse. Those for versican are in the order: human, mouse, chicken. 
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CONSENSUS CRD SEQUENCES 
MABA RAT IMSB/2MSB : 
E-SEEECTIN HUMAN IESL 
OBSERVED SEC STRUCTURE: 
DSSP IMSB A-chaln : 
DSSP IMSB B-chaln : 
DSSP 2MSB A-chaln : 
DSSP 2MSB B-chain : 
DSSP IESL 
OBSERVED ACCESSIBILITY: 
COMPARER IMSB A-chain : 
COMPARER IMSB B-chain : 
COMPARER 2MSB A-chain : 
COMPARER 2MSB B-chain : 
COMPARER IESL 
PREDICTED SEt STRUCTURE 
GOR I prediction: 
GOR I l l  prediction: 
Chou-Fasman prediction: 
SAPIENS prediction: 
PHD prediction: 
PREDICTED ACCESSIBILITY 
Elsenberg hydropathy : 
SAPIENS accessibi l i ty:  
PHD accessibi l i ty:  
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Fig. 2. Comparison of the observed and predicted secondary structures and solvent accessibilities for 5 CRD crystal structures and 129 CRD 
sequences with the predictions from 59 PTR sequences. Residue numberings are taken from the consensus CRD and PTR sequence alignments. 
The crystal structures have Brookhaven codes lmsb, 2msb and lesl. The consensus secondary structures are indicated by arrowed regions show- 
ing (x-helix (A) and 13-strand (B) locations. The DSSP output is denoted by: H, co-helix; E, 13-strand; other symbols are defined in Section 2. 
The secondary structure predictions are denoted by: A, o~-helix; B, 13-strand; t, turn; c, coil; 1, loop; i, buried coil; o, exposed coil. The ob- 
served accessibilities have values of 0-9 (Section 2), with 0-1 corresponding to buried (b) and 2-9 to exposed (e). 
3.  Resu l ts  
3.1. Sequence alignments and residue conservation 
The al ignment of 59 PTR sequences on the basis of residue 
similarities and minimal gap formation required only five 
short gaps (Fig. 1). The consensus length of the PTR was 
97 residues. Both these results agree with previous analyses 
[5,8]. The proteoglycan subgroup (link protein, aggrecan, bre- 
vican, neurocan, versican) with 48 sequences was distinct from 
that of the CD44 cell surface receptor with 9 sequences. Res- 
idue conservation within the PTR superfamily was found to 
be high, with 19 of the 97 residues showing over 90% con- 
servation and 37 of the 97 residues showing over 70% con- 
servation. The highest conservation is found for the 4 Cys 
residues, together with 3 aromatic and 9 aliphatic residues 
(Fig. 1). These are presumed to form a hydrophobic core 
Table 1 
THREADER analyses of PTR and CRD sequences 
Sequences Rank a Matched Mean Mean 
fold b position c Z-score a 
59 PTRs 1 2msb 4 + 5 -2.5 + 0.7 
2 lfus 12+ 13 -1.7+0.9 
3 l i lb 12-+24 --1.5-+ 1.7 
129 CRDs 1 2msb 7+22 -2 .2+ 1.3 
aThe top scoring three folds of 254 are listed. 
bBrookhaven database codes. 
°The mean position _+ standard eviation of the 59 PTR and 129 CRD 
sequences in the sorted list of 254 folds after threadings. 
dMean pairwise interaction energy Z-score+standard deviation for 
the matched fold in the 59 PTR and 129 CRD threadings. 
within the PTR. There are also 3 small conserved residues. 
These highly conserved residues occur in both the proteogly- 
can and CD44 subgroups except for Ala26 which is mostly 
replaced by Ser26 in CD44. In addition, Arg9 or Lys l l  is 
conserved in all the PTRs except in the fourth PTR of aggre- 
can. Arg56, Arg63 and Arg75 are conserved in virtually all the 
proteoglycan subgroup, and Arg58 is conserved in the CD44 
subgroup. Gln33 and Asp/Glu43 are conserved in 52 and 53 
sequences respectively. 
3.2. Protein fold recognition analyses 
The PTR sequences were scored for protein fold compat- 
ibility using THREADER with 254 known folds (Table 1). 
The use of all 59 sequences i more rigorous than the use of a 
single sequence [14]. The best scoring fold in terms of pairwise 
interaction energies was that to the CRD of rat mannose 
binding protein (2msb). This fold occurred 49 times out of 
59 in the top five best-scoring positions of the 254 folds. 
The Z-scores were particularly good for many sequences, 
and were less than -2 .7  in 23 cases and less than -3 .0  in 
16 cases. The mean position was 4 + 5, and the mean pairwise 
interaction energy Z-score was -2 .5  + 0.7. The 2msb hit was 
clearly superior to others that gave close Z-scores. The next 
best scoring fold was lfus (ribonuclease F1, 106 residues in an 
(~+13 fold), followed by l i lb  (interleukin 113, 153 residues, 12 
antiparallel I~-strands in a six-stranded [3-barrel), both of 
which showed noticeably greater variabil ity in rank position 
and weaker Z-scores. Control  THREADER calculations were 
performed for 129 CRD sequences [9]. As required, THREA-  
DER was able to correlate the 129 CRD sequences with its 
own fold (2msb) in top position (Table 1). 
214 N.C. Brissett, S.J. Perkins/FEBS Letters 388 (1996) 211-216 
A2 
A1 
Fig. 3. Molecular graphics model of the PTR. The CRD from mannose binding protein is shown to the left in the same orientation as the 
PTR model to the right, c~-Helices and 13-strands are identified as in Figs. 1 and 2. In the PTR model, the conserved residue Arg9/Lysll is 
well-defined, while the conserved residues Arg56, Arg63 and Arg75 occur in the ~-sheet region which is truncated in the PTR and are less well- 
defined. The position of the two disulphide bridges in each fold is denoted by thick black lines. 
3.3. Secondary structure and accessibility predictions 
In order to correlate the CRDs with the PTRs, the averaged 
observed and predicted secondary structure in the CRD 
superfamily ([9]; manuscript in preparation) is summarised 
in Fig. 2. Two a-helices A1 and A2 and seven [3-strands 
B1-B7 were consistently detected in five CRD crystal struc- 
tures by DSSP analysis, although some variability in the [3- 
strands is noticeable. Based on 129 CRD sequences, the ma- 
jority votes from five predictions howed that all nine features 
could be detected with the exception of B6 which forms part 
of Ca 2+ binding site 2 in mannose binding protein and E- 
selectin. In the crystal structures, the alternating e and b val- 
ues for the solvent accessibilities of the m-helices A1 and A2 
correspond to amphipathic structures, which was correctly 
predicted. The l-strands B3, B5 and B7 were observed to be 
buried, which was predicted correctly for B3 and B7. The [3- 
strands B1, B2, B4 and B6 were observed to be amphipathic, 
and this was predicted correctly for B1, B2 and B4. These 
results justify the application of prediction methods to the 
CRD superfamily, and in turn to the PTRs. 
The consensus secondary structure predictions for the PTR 
superfamily corresponded closely with the CRDs. The two 
predicted PTR m-helices A1 and A2 are close to A1 and A2 
in the CRDs. Both were predicted to be amphipathic as ob- 
served in the CRDs. The two predicted PTR [3-strands B1 and 
B2 also correlate well with the CRDs. PTR B7 correlates very 
well with CRD B7 as both contain a Cys residue that is 
bridged with one in PTR A1 [28] and CRD A1, and both 
B7 13-strands are hydrophobic. The PTR residues 47-85 cor- 
respond to the CRD residues 68-126, but this region is 20 
residues shorter than that of the CRD. In this region, the 
predicted PTR I~-strands B3 and B5 may be correlated with 
B3 and B5 in the CRDs, although B3 is now shifted in posi- 
tion. The PTR B6 was not predicted, but neither was it pre- 
dicted in the CRD. 
3.4. Molecular graphics analyses and modelling of the predicted 
PTR fold 
The topology of the CRD 2msb fold fully accounts for the 
PTR prediction: (i) In the view shown in Fig. 3, the 13-strands 
B1, B7 and B2 in the CRD form an antiparallel 13-sheet at the 
base which is flanked by the two a-helices A1 and A2 on 
either side, and stabilised by a disulphide bridge. This topol- 
ogy accounts for the hydrophobic nature of B7 at the centre 
of the 13-sheet. The best-predicted PTR c~-helices A1 and A2 
and the 13-strands B1, B2 and B7 are in full agreement with 
this topology. This includes the conserved PTR disulphide 
bridge Cys21-Cys91. (ii) The antiparallel I~-sheet B3-B5-B6 
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Fig. 4. Sequence alignment of the two PTRs from human link protein with the CRDs of rat mannose binding protein and E-selectin. This 
alignment is used for homology modelling. Residue identities between the two PTRs and two CRDs are indicated by vertical strokes. When 
either of the two residues in a pair of PTRs or CRDs is matched with the other pair, a vertical stroke indicates this correlation. 
Exon boundaries for the PTR and CRD domains in aggrecan are marked. The two Ca 2+ binding residues in lmsb/2msb and lesl are indicated 
by '1' and '2'. 
form an upper region that is slightly different in the CRDs of 
mannose binding protein (lmsb/2msb) and E-selectin (lesl). 
This region corresponds to the largest differences between 
the predicted PTR and observed CRD sequences. As 51 of 
the 59 residues between positions 68 126 in the CRD are in 
loop conformations, no firm conclusions can be inferred for 
the ]3-strands in this part of the PTR fold. It seems likely that 
at least B3 and B5 are present in the [3-sheet region, as the 
topology of Fig. 3 suggests that the connection can be formed 
with B7 even if B6 was not present, and the innermost two ]3- 
strands B3 and B5 of the [3-sheet were identified in the pre- 
diction (Fig. 2). 
The predicted PTR topology was tested by the construction 
of a molecular graphics model. The lmsb/2msb fold was used 
as this gives a better alignment with the PTR from human 
link protein than the lesl fold (Fig. 4). Interestingly, the 7- 
residue insertion between residues 77-78 in aggrecan, brevi- 
can, neurocan and versican (Fig. 1) is the same as that ob- 
served at residues 11~117 in the lesl sequence for E-selectin. 
Sequence alignment of the PTR and CRD in Fig. 4 show that 
many residue similarities exist between B1 and B3, and again 
between B5 and 87, and this was used to produce a model 
that was stereochemically satisfactory according to PRO- 
CHECK. Energy refinement was able to generate a possible 
structure incorporating the required disulphide bridge be- 
tween Cys45 and Cys66 on two neighbouring loops (Fig. 3). 
It was easier to model 86 as a loop rather than as a [3-strand 
as Fig. 4 showed that this segment had lost two residues in the 
PTR sequence compared to that of the CRD. B4 in the CRD 
is not part of a [3-sheet, and corresponds to a sequence dele- 
tion (Fig. 4) that is readily achieved in the PTR model. 
4.  D iscuss ion  
The inspection of our earlier secondary structure predic- 
tions for the PTRs and CRDs first raised the possibility 
that both superfamilies have similar folds [8,9]. This premise 
is supported by a combination of (i) protein fold recognition 
analyses; (ii) comparative predictions of secondary structures 
and accessibilities; (iii) sequence alignments and molecular 
graphics analyses. An atomic structure determination will be 
required to confirm the prediction. It should be noted that the 
prediction of a model by threading is not the same as the 
construction of a model by simple homology. Nonetheless 
the present study means that protein folds are known for all 
the domain types found in link protein and aggrecan [1 3], 
and all can be modelled. 
The structural analysis of the PTR and CRD folds suggest 
that B1-A1-B2-A2-B7 forms a conserved cd]3 core framework 
which provides a platform for two types of ]3-sheet region in 
the PTR and CRD superfamilies. In effect, B1-A1-B2-A2 
form a central slot for the insertion of the hydrophobic ]3- 
strand B7, which is then held in place by a disulphide bridge 
between A1 and B7 (Fig. 3). Interestingly, gene structures for 
aggrecan shows that B1-A1-B2-A2 are encoded by exons 4 
and 8 in the first and third PTRs of aggrecan (Fig. 4), exon 
4 also encodes this region in the first PTR of versican, and 
exon 2 likewise in the PTR of CD44 [29 32]. The CRD of 
aggrecan is encoded by three exons, and B1-A1-B2-A2 corre- 
sponds to the first of these, namely exon 14 [29,30]. In fact, 
three exons encode the group I, II and VI classes of CRDs [7]. 
The CRD residues that form the Ca 2+ and carbohydrate 
binding sites 1 and 2 in mannose binding protein and E-se- 
lectin are found in the [3-sheet region (Fig. 4). Link protein 
does not bind Ca 2+, and this concurs with the absence of 
these CRD residues in the PTRs. Instead Asp/Glu43 is con- 
served in many PTRs. Link protein is reported to possess two 
Zn 2+ binding sites, of which at least one is found on the first 
PTR domain. Link protein also binds Ni 2+ and Co 2+ but not 
Mg 2+ or Ca 2+ [33,34]. 
The PTR model makes possible an analysis for possible 
hyaluronate binding sites. Basic residues in link protein have 
been implicated in hyaluronate binding [35,36]. Two sets of 
these can be considered: (i) Arg9 is conserved in the PTRs of 
CD44 (Fig. 1). Removal of Arg9 by site-specific mutagenesis 
abolished hyaluronate binding [37], and other evidence sup- 
ports this role [38]. Such a hyaluronate binding site at Arg9/ 
Lys 11 lies on an exposed surface loop (Fig. 3). Arg9/Lysl 1 is 
conserved in all the PTRs of Fig. 1 except in the second PTR 
of the aggrecan G2 domain when it is replaced by Gln l  1. As 
G2 in aggrecan does not bind hyaluronate [6,39,40], this is 
supportive of the proposed binding site. (ii) Other conserved 
Arg residues occur at Arg56, Arg63 and Arg75 in the [3-sheet 
region of the proteoglycan subgroup (Figs. 1 and 3). The 
monoclonal antibody 8-A-4 binds to link proteins from 
many species and to proteoglycans [40,41]. Sequence studies 
show that its epitope has the sequence AGWLXDXSVXYPI  
[41], which includes Arg56 except when this is replaced by 
Gln56 in the first PTR of link protein. This epitope encom- 
passes B3, and is located on a loop adjacent o that bearing 
Arg9/Lysl l  (Fig. 3). The link protein peptides WDKERS-  
RYDV/PDKKHKLYGV and QYPITKPREP/RYPISRPR- 
KR inhibit hyaluronate binding, although this has been re- 
cently questioned [38,42,43]. The second peptide pair 
216 N.C. Brissett, S.J. PerkinslFEBS Letters 388 (1996) 211~16 
correspond to Arg56 and Arg63. The involvement of Arg56 
and Arg63 is compatible with the PTR model. 
In summary, as discussed in [38,42], the conserved basic 
residues Arg9/Lysl 1, Arg56 and Arg63 have been implicated 
in hyaluronate binding in the proteoglycan subgroup of 
PTRs, and together with Arg75 all four are located in sur- 
face-exposed positions proximate to one another on one face 
of the PTR model. Two of these, Arg9/Lysl 1 and Arg58, are 
likewise conserved in the CD44 subgroup. The PTR model 
will be of value for future functional and structural studies 
of hyaluronate binding. 
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